The production of growth factors and other cytokines by recombinant DNA technology has facilitated assessment of their in vivo therapeutic potential. Alpha Interferon has been used effectively in the treatment of hairy cell leukaemia and maintenance regimens for myeloma, while IL-2 immunotherapy has been used as an alternative to chemotherapy in advanced stages of melanoma or renal cell carcinoma. Granulocyte and Granulocyte-Macrophage Colony Stimulating Factor have recen'tly been shown to be of great promise in ameliorating neutropenia associated with intensive chemotherapy. This paper reports the results of a Phase I dose toxicity clinical trial of Interleukin 4 (IL-4) prior to determining potential anti-neoplastic properties in patients with malignant disease.
IL-4 was first described in 1982 when its role as a distinct B cell growth factor was recognised (Howard, 1982) . It is produced mainly by CD4 helper T lymphocytes and exhibits a wide range of effects as an immunoregulatory lymphokine and as a haemopoietic growth factor (Paul, 1991) .
During the maturation of early B cells, has been shown to induce surface IgM expression and inhibit expression of the primitive B cell marker, CD5 (Hofman et al., 1988; Defrance et al., 1989) . IL-4 stimulates B cell proliferation in vitro and upregulates CD23, the low affinity IgE receptor, which when secreted can act as a mitogen for B cells (Gordon et al., 1988) . It can also upregulate MHC class II antigens (Noelle et al., 1984) and stimulate or inhibit immunoglobulin production and isotype switching to favour IgE production (Snapper et al., 1988) .
In addition to its effects on B cell differentiation and development, IL-4 can influence T cell viability and act as a proliferative stimulus to preactivated T cells (Hu Li et al., 1987) . IL-4 also stimulates the differentiation of antigen specific cytotoxic T lymphocytes (Horohow et al., 1988) but, in human studies, does not induce lymphokine activated killer (LAK) cell activity. Indeed, IL-4 may stimulate or inhibit Interleukin 2 (IL-2) induced LAK activity although inhibition can in part be overcome by gamma interferon (Han et al., 1988; Spits et al., 1988; Widmer et al., 1987) .
IL-4 has pleiotropic effects on various other haemopoietic cells. Combinations of IL-4 with IL-3, G-CSF, erythropoietin, GM-CSF or M-CSF may be stimulatory or inhibitory for myeloid progenitor cells (Jansen et al., 1989; Favre et al., 1990; Broxmeyer et al., 1988) .
From these data, it is apparent that IL-4 affects a broad spectrum of cells and it is not surprising that the IL-4
receptor (IL-4R) is expressed by cell lines of several lineages, including lymphoid, myeloid, fibroblast, endothelial and epithelial (Cabrillat et al., 1987; Park et al., 1987) . The receptor is a single high affinity glycoprotein and is maximally upregulated by (Zuber et al., 1990) .
While the precise physiological functions of IL-4 still remain to be determined, it has emerged that IL-4 has potent anti-tumour effects. These effects have been demonstrated using transplantable malignant cell lines in murine experiments. The tumour cell lines used were characteristically poorly immunogenic and rapidly lethal when injected subcutaneously into mice (Tepper et al., 1989) . Transfection of the IL-4 gene into these cells and subsequent expression of IL-4 did not influence their in vitro growth characteristics, but prevented in vivo growth. The anti-tumour effects exerted by IL-4 were localised to the immediate vicinity of the tumour which was heavily infiltrated with neutrophils, eosinophils and macrophages.
Contralateral non-transfected cells, injected subcutaneously into mice carrying IL-4 transfected tumour cells were not rejected by the mice and showed little or no evidence of infiltration with granulocytes and macrophages. Perilymphatic injection of low doses of IL-4 around lymph nodes draining nontransfected tumours resulted in suppression of tumour development (Bosco et al., 1990) while contralateral simultaneous injection of tumour cells without local IL-4 led to unrestrained proliferation. Mice exposed to tumour and IL-4 were able to reject further challenges with tumour cell alone. Adoptive passive transfer experiments using sublethally irradiated mice suggested that this memory effect was mediated by CD4-T lymphocytes. The anti-tumour effects of IL-4 do not seem to be confined to experimentally induced tumours since growth inhibition in response to IL-4 has been demonstrated in 56% of freshly isolated specimens of human lymphoid malignancies (Taylor et al., 1990) .
The immunomodulatory effects of IL-4 taken in conjunction with the demonstrated anti-tumour effects in vitro and in vivo, have encouraged the proposal that IL-4 may be of use in the treatment of malignant disease. A Phase I trial was undertaken to evaluate the toxicity and biological effects of IL-4 given at increasing dosage for prolonged periods using the subcutaneous route. (Miller et al., 1981) Twenty ml of heparinised venous blood were collected on the same days. Bone marrow cells for in vitro manipulation were collected in Iscove's medium (Gibco) with 50 units of preservative free heparin (CP Pharmaceuticals Ltd). Three aliquots of this suspension were prepared and clonal assays performed as described previously (Testa, 1985) BFU-E (Burst forming unit -erythroid), GM-CFC (Granulocyte macrophage-colony forming cells) and Mix-CFC (Mixed lineage -colony forming cells).
Materials and methods

Study design
The remaining fraction of bone marrow cells was assayed for IL-4R using a method previously described (Heyworth et al., 1991 Ghosh et al. (1989) .
LAK cells were generated by incubating 2 x 106 ml1 PBMC with 200 I ml1 IL-2 (Cetus, Emeryville CA) in six well plates for 4 days. Cells were then harvested and washed twice before assessment of LAK activity.
PBMC were assessed for their ability to proliferate in the presence of mitogens over the trial period. Three concentrations of each mitogen were placed in 96 well plates in triplicate (100 lwell') to which 100il of PBMC at 2 x 106 ml-1 were added. Following an incubation at 37°C for 3 days the cells received 1 gACi of 3H-thymidine 4 h prior to harvesting by a cell harvester (Dynatech) onto glass fibre paper. There were modest but statistically significant elevations in neutrophils (P<0.00005) and platelets (P=0.0024) during cycle three of dosing. This rise was most evident at day 36. In patient 7 at 5 1tg kg-' the rise in neutrophils and platelets was substantially higher than in patients at 0.5 or 1.0 yg kg-' (Figures 1 and 2 ). There were no significant changes in lymphocyte, eosinophil, basophil or monocyte levels and fluctuations in haemoglobin were unrelated to IL-4 dosing.
Bone marrow aspirates, sampled pretreatment and on days Changes in immune function induced by IL-4 were assessed indirectly but IL-4 did not enhance delayed hypersensitivity reactions as judged by skin testing with defined allergens since in all patients the skin test score fell or remained at zero. The in vitro cytotoxicity of PBMC was assayed against the cultured tumour targets K562 (NK sensitive) and Daudi (NK resistant, LAK sensitive) in all patients. Pretreatment cytotoxicity against K562 varied from 2-39% with five patients showing positive cytotoxicity (above 10%). In patients 4 and 6 cytotoxicity towards K562 increased above pretreatment values on day 28 from 22 to 33% and 11 to 42% respectively, but by day 56, values had decreased to 3 and 6%. In all other patients cytotoxicity towards K562 decreased or remained the same over the treatment period. There were no significant changes in cytotoxicity towards Daudi cells during the treatment period. In all nine patients examined, the PBMC contained LAK cell precursors estimated by induction of cytotoxicity against the NK resistant, LAK sensitive target Daudi by incubation with IL-2 in vitro for 4 days. There were no significant quantitative changes observed of in vitro LAK cell activity in serial blood samples taken throughout the rIL-4 treatment and values were comparable to normal controls, i.e. 60-80%.
To evaluate whether or not in vivo IL-4 administration has any effect on proliferative responses, PBMC obtained at various times pre and post treatment were incubated with different doses of PHA, PWM, SAC, IL-2 and IL-4. Two of the three patients at 0.5 ytg kg-' had 2-fold increased proliferative response to PWM on day 15 but no significant increase in response to PHA. Of the three patients who received 1 jg kg-' IL-4, one had a 3-fold increase in proliferative response to PHA on days 15 and two had 2-4-fold increased proliferative response to PWM but these decreased 
% (9) - (8) (Conrad, 1990; Cairns & Gordon, 1990 However, in vivo IL-4 administration did not have any measurable effect on NK activity or induce LAK cell activity. This observation is in agreement with in vitro studies (Kawakami et al., 1989) on the effects of IL-4 alone on unstimulated PBMC. In vitro and in vivo IL-2 primed cells can however show increased cytotoxicity and proliferation when combined with IL-4 in vitro (Treismann et al., 1990) . It has been shown that IL-4 can augment proliferation of lymphocytes in the presence of mitogens or preactivated cells in vitro (Spits et al., 1987) . In our study, slight increases were observed in the proliferative response to PWM and PHA on dl5 midway through a treatment cycle which may indicate activation of the patients lymphocytes in vivo. In vitro studies have shown IL-4 to inhibit proliferation of lymphocytes when used simultaneously with IL-2, but at the end of the third treatment cycle no inhibition was observed in the proliferative response to IL-2, and in four patients (2, 4, 5 and 6) it was augmented compared to pretreatment values. These observations on the augmentation of proliferative response suggest that IL-4 has stimulatory effects on subsets of lymphocytes in vivo and that combination therapy using IL-2 and IL-4 may be of value.
Preliminary data on the use of IL-4 in other Phase I trials have recently appeared. In one study of ten patients a maximum tolerated intravenous dose of 10 fg kg-I was reached (Mier et al., 1991) . Reported toxicities including nausea, vomiting, fatigue, anorexia, headache, dyspnoea, hyponatraemia and prolonged PT or PTT. In only one patient were hepatic enzymes elevated. Another study (Freimann et al., 1991) of 27 patients achieved an intravenous dose of 160 fg m2 day-' (18 patients) and a subcutaneous dose of 5,ug kg-' day-' (nine patients) without reaching a maximum tolerated dose. Common toxicities were fever, sinus congestion and headache.
Asymptomatic elevations in liver enzymes necessitating dose reduction were predominantly a feature of subcutaneous dosing. Pharmacokinetic data for intravenous or subcutaneous routes of administration are not yet available but may explain the difference in hepatotoxicity.
We have observed 5 pg kg-' day-' to be the limiting dose given subcutaneously. While we have seen no clear tumour responses, the transient fall in myeloma paraprotein during IL-4 dosing noted in patient 8 may suggest some susceptibility of this tumour to IL-4. Certainly this would be in line with reports from Maher et al. (1990) or responses to IL-4 by two patients with lymphoproliferative disease and the in vitro work of Taylor et al. (1990) . These reports indicate that patients with lymphoproliferative disorders should be selected for Phase II trials.
